Nevertheless, the generation transient hypoxia in response to anti-VEGF treatment, may trigger the mobilization of cancer stem cells (CSCs), thus limiting the clinical effectiveness of conventional angiogenic-impairing agents [218,219,220]. Here, VEGFA is linked to cancer.